Company intelligence / Profile preview

Yuxi Zerun Biotechnology Co., Ltd.

Yuxi City, Yunnan Province, Chinazerunbio.com ↗

Ownership: Private
Development stage: Commercial

Overview

The company has developed a bivalent HPV vaccine (Walrinvax) that received WHO prequalification in August 2024 and was licensed for use in China on March 22, 2022. The vaccine targets HPV types 16 and 18, which are the most common virus types leading to cervical cancer.

Therapeutic areas: OncologyWomen's Health
Modalities: Recombinant vaccinesGenetically engineered subunit vaccines
Industry: Biotech

Drug pipeline

4 assets

bivalent HPV vaccine

Commercial

Indications: HPV infection prevention

3 more assets in the full pipeline.

Request access →

Partnerships

Bill & Melinda Gates FoundationPATH

Beyond the preview

Go deeper on Yuxi Zerun Biotechnology Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yuxi Zerun Biotechnology Co., Ltd..

Explore the full profile